Talk:Axitinib
Latest comment: 6 years ago by Rod57 in topic Encouraging results in RCC from a trial in combination with a PD1-inhibitor pembrolizumab
| This is the talk page for discussing improvements to the Axitinib article. This is not a forum for general discussion of the article's subject. |
Article policies
|
| Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
 | This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||
| |||||||||||||||||||||
 | Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Axitinib.
|
trial on previously untreated RCC edit
ASCO: VEGF Blocker Active in Metastatic RCC is only phase II but suggests it may also be effective in previously untreated RCC. - Rod57 (talk) 14:57, 10 June 2012 (UTC)
Encouraging results in RCC from a trial in combination with a PD1-inhibitor pembrolizumab edit
Says 'Unprecedented' 73% Response Rate With Combo in Untreated RCC - suggests due to it being a more selective VEGF inhibitor. These results gained FDA Breakthrough designation for the combination. - Rod57 (talk) 18:03, 19 February 2018 (UTC)